DOI QR코드

DOI QR Code

Effects of Gintonin-enriched fraction on the gene expression of six lysophosphatidic receptor subtypes

  • Lee, Rami (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) ;
  • Lee, Byung-Hwan (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) ;
  • Choi, Sun-Hye (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) ;
  • Cho, Yeon-Jin (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) ;
  • Cho, Han-Sung (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University) ;
  • Kim, Hyoung-Chun (Neuropsychopharmacology and Toxicology program, College of Pharmacy, Kangwon National University) ;
  • Rhim, Hyewhon (Center for Neuroscience, Korea Institute of Science and Technology) ;
  • Cho, Ik-Hyun (Department of Convergence Medical Science, Department of Science in Korean Medicine, Graduate School, Kyung Hee University) ;
  • Rhee, Man Hee (Laboratory of Veterinary Physiology and Cell Signaling, College of Veterinary Medicine, Kyungpook National University) ;
  • Nah, Seung-Yeol (Ginsentology Research Laboratory and Department of Physiology, College of Veterinary Medicine, Konkuk University)
  • Received : 2020.10.28
  • Accepted : 2021.02.17
  • Published : 2021.09.30

Abstract

Background: Gintonin, isolated from ginseng, acts as a ginseng-derived lysophosphatidic acid (LPA) receptor ligand and elicits the [Ca2+]i transient through six LPA receptor subtypes (LPARSs). However, the long-term effects of gintonin-enriched fraction (GEF) on the gene expression of six LPARSs remain unknown. We examined changes in the gene expression of six LPA receptors in the mouse whole brain, heart, lungs, liver, kidneys, spleen, small intestine, colon, and testis after long-term oral GEF administration. Methods: C57BL/6 mice were divided into two groups: control vehicle and GEF (100 mg/kg, p.o.). After 21-day saline or GEF treatment, total RNA was extracted from nine mouse organs. Quantitative-real-time PCR (qRT-PCR) and western blot were performed to quantify changes in the gene and protein expression of the six LPARSs, respectively. Results: qRT-PCR analysis before GEF treatment revealed that the LPA6 RS was predominant in all organs except the small intestine. The LPA2 RS was most abundant in the small intestine. Long-term GEF administration differentially regulated the six LPARSs. Upon GEF treatment, the LPA6 RS significantly increased in the liver, small intestine, colon, and testis but decreased in the whole brain, heart, lungs, and kidneys. Western blot analysis of the LPA6 RS confirmed the differential effects of GEF on LPA6 receptor protein levels in the whole brain, liver, small intestine, and testis. Conclusion: The LPA6 receptor was predominantly expressed in all nine organs examined; long-term oral GEF administration differentially regulated LPA3, LPA4, and LPA6 receptors in the whole brain, heart, lungs, liver, kidneys, small intestine, and testis.

Keywords

Acknowledgement

This work was supported by the Ministry of Science, ICT, and Future Planning for the Basic Science Research Program (NRF2020R1F1A1058460) to S. Y. Nah.

References

  1. Moreno-Fernandez RD, Tabbai S, Castilla-Ortega E, Perez-Martin M, Estivill-Torrus G, Rodriguez de Fonseca F, Santin LJ, Pedraza C. Stress, depression, resilience and ageing: a role for the LPA-LPA1 pathway. Curr Neuropharmacol 2018;16:271-83. https://doi.org/10.2174/1570159X15666170710200352
  2. Lee BH, Choi SH, Kim HJ, Jung SW, Kim HK, Nah SY. Plant lysophosphatidic acids: a rich source for bioactive lysophosphatidic acids and their pharmacological applications. Biol Pharm Bull 2016;39:156-62. https://doi.org/10.1248/bpb.b15-00575
  3. Afroz S, Yagi A, Fujikawa K, Rahman MM, Morito K, Fukuta T, Watanabe S, Kiyokage E, Toida K, Shimizu T, et al. Lysophosphatidic acid in medicinal herbs enhances prostaglandin E2 and protects against indomethacin-induced gastric cell damage in vivo and in vitro. Prostaglandins Other Lipid Mediat 2018;135:36-44. https://doi.org/10.1016/j.prostaglandins.2018.01.003
  4. Hwang SH, Shin TJ, Choi SH, Cho HJ, Lee BH, Pyo MK, Lee JH, Kang J, Kim HJ, Park CW, et al. Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity. Mol Cells 2012;33:151-62. https://doi.org/10.1007/s10059-012-2216-z
  5. Nakane S, Tokumura A, Waku K, Sugiura T. Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions. Lipids 2001;36:413-9. https://doi.org/10.1007/s11745-001-0737-1
  6. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 2002;43:2049-55. https://doi.org/10.1194/jlr.M200242-JLR200
  7. Choi SH, Jung SW, Kim HS, Kim HJ, Lee BH, Kim JY, Kim JH, Hwang SH, Rhim H, Kim HC, et al. A brief method for preparation of gintonin-enriched fraction from ginseng. J Ginseng Res 2015;39:398-405. https://doi.org/10.1016/j.jgr.2015.05.002
  8. Nah SY. Ginseng ginsenoside pharmacology in the nervous system: involvement in the regulation of ion channels and receptors. Front Physiol 2014;5:98. https://doi.org/10.3389/fphys.2014.00098
  9. Kim HJ, Jung SW, Kim SY, Cho IH, Kim HC, Rhim H, Kim M, Nah SY. Panax ginseng as an adjuvant treatment for Alzheimer's disease. J Ginseng Res 2018;42:401-11. https://doi.org/10.1016/j.jgr.2017.12.008
  10. Pyo MK, Choi SH, Shin TJ, Hwang SH, Lee BH, Kang J, Kim HJ, Lee SH, Nah SY. A simple method for the preparation of crude gintonin from ginseng root, stem, and leaf. J Ginseng Res 2011;35:209-18. https://doi.org/10.5142/jgr.2011.35.2.209
  11. Pyo MK, Lim YH, Lee S, Lee BH, Shin TJ, Hwang SH, et al. Novel glycol-lipoproteins from ginseng. J Ginseng Res 2008;35:12. https://doi.org/10.5142/jgr.2011.35.1.012
  12. Cho HJ, Choi SH, Kim HJ, Lee BH, Rhim H, Kim HC, Hwang SH, Nah SY. Bioactive lipids in gintonin-enriched fraction from ginseng. J Ginseng Res 2019;43:209-17. https://doi.org/10.1016/j.jgr.2017.11.006
  13. Lee K, Jin H, Chei S, Oh HJ, Choi SH, Nah SY, Lee BY. The gintonin-enriched fraction of ginseng regulates lipid metabolism and browning via the cAMP-protein kinase a signaling pathway in mice white adipocytes. Biomolecules 2020;10.
  14. Kim S, Kim MS, Park K, Kim HJ, Jung SW, Nah SY, Han JS, Chung C. Hippocampus-dependent cognitive enhancement induced by systemic gintonin administration. J Ginseng Res 2016;40:55-61. https://doi.org/10.1016/j.jgr.2015.05.001
  15. Nam SM, Choi SH, Cho HJ, Seo JS, Choi M, Nahm SS, Chang BJ, Nah SY. Ginseng gintonin attenuates lead-induced rat cerebellar impairments during gestation and lactation biomolecules, vol. 10; 2020.
  16. Hwang SH, Lee BH, Choi SH, Kim HJ, Won KJ, Lee HM, Rhim H, Kim HC, Nah SY. Effects of gintonin on the proliferation, migration, and tube formation of human umbilical-vein endothelial cells: involvement of lysophosphatidic-acid receptors and vascular-endothelial-growth-factor signaling. J Ginseng Res 2016;40:325-33. https://doi.org/10.1016/j.jgr.2015.10.002
  17. Choi SH, Kim HJ, Cho HJ, Park SD, Lee NE, Hwang SH, Rhim H, Kim HC, Cho IH, Nah SY. Gintonin-mediated release of astrocytic vascular endothelial growth factor protects cortical astrocytes from hypoxia-induced cell damages. J Ginseng Res 2019;43:305-11. https://doi.org/10.1016/j.jgr.2018.05.006
  18. Choi SH, Lee R, Nam SM, Kim DG, Cho IH, Kim HC, Cho Y, Rhim H, Nah SY. Ginseng gintonin, aging societies, and geriatric brain diseases. Integrative Medicine Research 2021;10.
  19. Lee R, Lee NE, Choi SH, Nam SM, Kim HC, Rhim H, Cho IH, Hwang SH, Nah SY. Effects of gintonin-enriched fraction on hippocampal gene expressions. Integrative Med Res 2021.
  20. Lee BH, Kim HK, Jang M, Kim HJ, Choi SH, Hwang SH, Kim HC, Rhim H, Cho IH, Nah SY. Effects of gintonin-enriched fraction in an atopic dermatitis animal model: involvement of autotaxin regulation. Biol Pharm Bull 2017;40:1063-70. https://doi.org/10.1248/bpb.b17-00124
  21. Kim HJ, Kim JY, Lee BH, Choi SH, Rhim H, Kim HC, Ahn SY, Jeong SW, Jang M, Cho IH, et al. Gintonin, an exogenous ginseng-derived LPA receptor ligand, promotes corneal wound healing. J Vet Sci 2017;18:387-97. https://doi.org/10.4142/jvs.2017.18.3.387
  22. Choi JH, Jang M, Oh S, Nah SY, Cho IH. Multi-target protective effects of gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated model of Parkinson's disease via lysophosphatidic acid receptors. Front Pharmacol 2018;9:515. https://doi.org/10.3389/fphar.2018.00515
  23. Jang M, Choi JH, Chang Y, Lee SJ, Nah SY, Cho IH. Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: activation of the Nrf2 pathway through lysophosphatidic acid receptors. Brain Behav Immun 2019;80:146-62. https://doi.org/10.1016/j.bbi.2019.03.001
  24. Jo MG, Ikram M, Jo MH, Yoo L, Chung KC, Nah SY, Hwang H, Rhim H, Kim MO. Gintonin mitigates MPTP-induced loss of nigrostriatal dopaminergic neurons and accumulation of alpha-synuclein via the Nrf2/HO-1 pathway. Mol Neurobiol 2019;56:39-55. https://doi.org/10.1007/s12035-018-1020-1
  25. Kim HJ, Shin EJ, Lee BH, Choi SH, Jung SW, Cho IH, Hwang SH, Kim JY, Han JS, Chung C, et al. Oral administration of gintonin attenuates cholinergic impairments by scopolamine, amyloid-beta protein, and mouse model of alzheimer's disease. Mol Cells 2015;38:796-805. https://doi.org/10.14348/MOLCELLS.2015.0116
  26. Lee NE, Park SD, Hwang H, Choi SH, Lee RM, Nam SM, Choi JH, Rhim H, Cho IH, Kim HC, et al. Effects of a gintonin-enriched fraction on hair growth: an in vitro and in vivo study. J Ginseng Res 2020;44:168-77. https://doi.org/10.1016/j.jgr.2019.05.013
  27. Yung YC, Stoddard NC, Mirendil H, Chun J. Lysophosphatidic Acid signaling in the nervous system. Neuron 2015;85:669-82. https://doi.org/10.1016/j.neuron.2015.01.009
  28. Contos JJ, Ishii I, Chun J. Lysophosphatidic acid receptors. Mol Pharmacol 2000;58:1188-96. https://doi.org/10.1124/mol.58.6.1188
  29. Radeff-Huang J, Seasholtz TM, Matteo RG, Brown JH. G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival. J Cell Biochem 2004;92:949-66. https://doi.org/10.1002/jcb.20094
  30. Chun J, Hla T, Lynch KR, Spiegel S, Moolenaar WH. International union of basic and clinical pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev 2010;62:579-87. https://doi.org/10.1124/pr.110.003111
  31. Geach TJ, Faas L, Devader C, Gonzalez-Cordero A, Tabler JM, Brunsdon H, Isaacs HV, Dale L. An essential role for LPA signalling in telencephalon development. Development 2014;141:940-9. https://doi.org/10.1242/dev.104901
  32. Suckau O, Gross I, Schrotter S, Yang F, Luo J, Wree A, Chun J, Baska D, Baumgart J, Kano K, LPA2. LPA4 , and LPA6 receptor expression during mouse brain development. Dev Dyn 2019;248:375-95. https://doi.org/10.1002/dvdy.23
  33. Gross I, Brauer AU. Modulation of lysophosphatidic acid (LPA) receptor activity: the key to successful neural regeneration? Neural Regen Res 2020;15:53-4. https://doi.org/10.4103/1673-5374.264452
  34. Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, Aoki J. LPA-producing enzyme PA-PLA(1)alpha regulates hair follicle development by modulating EGFR signalling. EMBO J 2011;30:4248-60. https://doi.org/10.1038/emboj.2011.296
  35. Hayashi R, Inoue A, Suga Y, Aoki J, Shimomura Y. Analysis of unique mutations in the LPAR6 gene identified in a Japanese family with autosomal recessive woolly hair/hypotrichosis: establishment of a useful assay system for LPA6. J Dermatol Sci 2015;78:197-205. https://doi.org/10.1016/j.jdermsci.2015.03.006
  36. Masago K, Kihara Y, Yanagida K, Hamano F, Nakagawa S, Niwa M, Shimizu T. Lysophosphatidic acid receptor, LPA6, regulates endothelial blood-brain barrier function: implication for hepatic encephalopathy. Biochem Biophys Res Commun 2018;501:1048-54. https://doi.org/10.1016/j.bbrc.2018.05.106